HC Wainwright Increases ADMA Biologics (NASDAQ:ADMA) Price Target to $18.00

ADMA Biologics (NASDAQ:ADMA) had its price objective upped by research analysts at HC Wainwright from $10.00 to $18.00 in a research note issued on Monday, Marketbeat.com reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 4.23% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Raymond James lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Cantor Fitzgerald increased their target price on ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, August 9th. Finally, Mizuho boosted their price target on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $17.27 on Monday. The business has a fifty day simple moving average of $11.90 and a 200-day simple moving average of $8.47. ADMA Biologics has a 52 week low of $3.06 and a 52 week high of $17.30. The company has a market cap of $4.00 billion, a P/E ratio of -848.00 and a beta of 0.55. The company has a quick ratio of 1.86, a current ratio of 5.21 and a debt-to-equity ratio of 0.91.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.08 by $0.05. The company had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. The firm’s revenue was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.02) EPS. Equities research analysts forecast that ADMA Biologics will post 0.35 EPS for the current year.

Insider Transactions at ADMA Biologics

In related news, CEO Adam S. Grossman sold 100,000 shares of ADMA Biologics stock in a transaction on Friday, June 14th. The shares were sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the transaction, the chief executive officer now owns 2,081,475 shares in the company, valued at approximately $22,313,412. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several hedge funds have recently modified their holdings of ADMA. Quest Partners LLC purchased a new position in ADMA Biologics in the 2nd quarter worth approximately $29,000. EntryPoint Capital LLC purchased a new position in shares of ADMA Biologics in the first quarter valued at $31,000. Simplicity Wealth LLC acquired a new stake in ADMA Biologics during the 1st quarter valued at $68,000. AJOVista LLC purchased a new stake in ADMA Biologics during the 4th quarter worth $77,000. Finally, Oxford Asset Management LLP acquired a new position in ADMA Biologics in the 4th quarter worth $83,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.